The changing face of hormonal therapy for prostate cancer

被引：7
作者：
Seruga, B. [1 ]
Tannock, I. F.
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
ANDROGEN-DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; PHASE-III TRIAL; RADICAL PROSTATECTOMY; METABOLIC SYNDROME; RADIATION-THERAPY; TESTOSTERONE SUPPRESSION; CARDIOVASCULAR-DISEASE; ARTERIAL STIFFNESS; AMERICAN-SOCIETY;
D O I：
10.1093/annonc/mdn477
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：79 / 85
页数：7
相关论文
共 55 条
[21]   Bilateral orchiectomy with or without flutamide for metastatic prostate cancer [J].
Eisenberger, MA ;
Blumenstein, BA ;
Crawford, ED ;
Miller, G ;
McLeod, DG ;
Loehrer, PJ ;
Wilding, G ;
Sears, K ;
Culkin, DJ ;
Thompson, IM ;
Bueschen, AJ ;
Lowe, BA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (15) :1036-1042
[22]   Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy [J].
Freedland, SJ ;
Humphreys, EB ;
Mangold, LA ;
Eisenberger, M ;
Dorey, FJ ;
Walsh, PC ;
Partin, AW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (04) :433-439
[23]   Who is the average patient presenting with prostate cancer? [J].
Greene, KL ;
Cowan, JE ;
Cooperberg, MR ;
Meng, MV ;
DuChane, J ;
Carroll, PR .
UROLOGY, 2005, 66 (5A) :76-82
[24]   Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer [J].
Han, M ;
Partin, AW ;
Zahurak, M ;
Piantadosi, S ;
Epstein, JI ;
Walsh, PC .
JOURNAL OF UROLOGY, 2003, 169 (02) :517-523
[25]   Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 [J].
Hanks, GE ;
Pajak, TF ;
Porter, A ;
Grignon, D ;
Brereton, H ;
Venkatesan, V ;
Horwitz, EM ;
Lawton, C ;
Rosenthal, SA ;
Sandler, HM ;
Shipley, WU .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3972-3978
[26]   Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer [J].
Keating, Nancy L. ;
O'Malley, A. James ;
Smith, Matthew R. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) :4448-4456
[27]   The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men [J].
Lakka, HM ;
Laaksonen, DE ;
Lakka, TA ;
Niskanen, LK ;
Kumpusalo, E ;
Tuomilehto, J ;
Salonen, JT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (21) :2709-2716
[28]   An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions [J].
Lawton, Colleen A. ;
DeSilvio, Michelle ;
Roach, Mack, III ;
Uhl, Valery ;
Kirsch, Robert ;
Seider, Michael ;
Rotman, Marvin ;
Jones, Christopher ;
Asbell, Sucha ;
Valicenti, Richard ;
Hahn, Stephen ;
Thomas, Charles R., Jr. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03) :646-655
[29]   Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline [J].
Loblaw, D. Andrew ;
Virgo, Katherine S. ;
Nam, Robert ;
Somerfield, Mark R. ;
Ben-Josef, Edgar ;
Mendelson, David S. ;
Middleton, Richard ;
Sharp, Stewart A. ;
Smith, Thomas J. ;
Talcott, James ;
Taplin, Maryellen ;
Vogelzang, Nicholas J. ;
Wade, James L., III ;
Bennett, Charles L. ;
Scher, Howard I. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1596-1605
[30]   American society of clinical oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer [J].
Loblaw, DA ;
Mendelson, DS ;
Talcott, JA ;
Virgo, KS ;
Somerfield, MR ;
Ben-Josef, E ;
Middleton, R ;
Porterfield, H ;
Sharp, SA ;
Smith, TJ ;
Taplin, ME ;
Vogelzang, NJ ;
Wade, JL ;
Bennett, CL ;
Scher, HI .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2927-2941
123456